How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Get the latest news and real-time alerts from Recursion Pharmaceuticals, Inc. (RXRX) stock at Seeking Alpha.

Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Get real-time Recursion Pharmaceuticals (RXRX) stock price, charts, news, and analyst ratings on Benzinga. Access forecasts, historical data, and expert insights to inform your investment decisions.

Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...